Immune Checkpoint Inhibitors in Glioblastoma Treatment
Author Information
Author(s): Baskaran Archit Bharathwaj, Kozel Olivia A., Venkatesh Omkar, Wainwright Derek A., Sonabend Adam M., Heimberger Amy B., Lukas Rimas Vincas
Hypothesis
Can immune checkpoint inhibitors improve treatment outcomes for glioblastoma patients?
Conclusion
Immune checkpoint inhibitors have not yet shown clear evidence of efficacy in glioblastoma treatment.
Supporting Evidence
- 117 clinical trials were identified, but most showed no improvement in survival for glioblastoma patients.
- Biomarker analyses suggest that some patients may benefit from immune checkpoint inhibitors.
- Current treatments for glioblastoma have significant unmet needs, highlighting the importance of exploring new therapies.
Takeaway
This study looked at many trials using special drugs to help the immune system fight brain tumors, but they didn't work well for most patients.
Methodology
A systematic review of clinical trials from ClinicalTrials.gov for immune checkpoint inhibitors in glioblastoma from 1950 to July 2024.
Limitations
The review only included agents with FDA approval, potentially missing other relevant treatments.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website